secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-118575
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconova reports Q3 net loss $5.4M; plans Phase 1/2a narazaciclib trial in endometrial cancer in 1Q23
--------------------------------------------------------------------------------

- Net loss of $5.4M ($0.26/share) vs $3.5M ($0.22) in Q3 2021; R&D expenses rose to $3.6M from $1.8M.
- Cash and equivalents $42.6M as of Sep 30, 2022, down from $55.1M at Dec 31, 2021; expects to fund operations into 2024.
- Plans to initiate Phase 1/2a trial of narazaciclib + letrozole in recurrent LGEEC in 1Q23; preliminary data expected 4Q23.
- Rigosertib/nivolumab trial in KRAS-mutated NSCLC showed one complete response and two partial responses in 14 evaluable patients.
- Rigosertib investigator-sponsored trials continue; Phase 2 melanoma trial on track for initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/0001104659-22-118575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/tm2230479d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-118575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer